GW epilepsy drug data positive

Investor's Business Daily

British biotech GW Pharmaceuticals (GWPH) reported positive safety and efficacy data from physicians treating epileptics with its drug Epidiolex, driving shares to an all-time high. GW plans to launch a more rigorous clinical trial of Epidiolex later this year. Leerink analyst Joseph Schwartz reiterated an outperform rating and raised his price target to 110 from 90. Shares rose 16.3% to 89.82 but fell 3.7% to 86.51 after hours.

Rates

View Comments (0)